# HILL STREET BEVERAGE COMPANY INC.

# CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

# FOR THE THREE-MONTH AND SIX MONTHS ENDED DECEMBER 31, 2020 AND 2019

(Expressed in Canadian dollars)

## NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

TORONTO, ON March 1, 2021

# Hill Street Beverage Company Inc.

# **Condensed Interim Consolidated Statements of Financial Position**

(Expressed in Canadian Dollars)

| Intangible assets 8 4<br>Property and equipment 7  TOTAL ASSETS 6  LIABILITIES Current Accounts payable and accrued liabilities 12 1 Lease liability – current 9  Lease liability non-current 9  Due to Lexaria Canpharm ULC 8 & 10 CEBA loan 10 Note payable 10 1 Convertible debenture 10  SHAREHOLDERS' EQUITY Share capital 11 16 Reserve 11 2 Deficit (17,- TOTAL SHAREHOLDERS' EQUITY 1  | ecember 31,<br>2020 | June 30<br>2020 |
|--|---------------------|-----------------|
| Current Cash and cash equivalents Accounts receivable 5 Other receivable 12 Inventory 6 Prepaid expenses Total current assets 1 Intangible assets 8 4 Property and equipment 7 TOTAL ASSETS 6 ILABILITIES Current Accounts payable and accrued liabilities 12 1 Lease liability – current 9 Lease liability – current 9 Lease liability non-current 9 Lease liability non-current 9 Lease liability non-current 9 Lease liability non-current 9 CEBA loan 10 Note payable 10 CEBA loan 10 Note payable 10 Cenvertible debenture 10 SHAREHOLDERS' EQUITY 5 Share capital 11 16 Reserve 11 20 Efici (17,: TOTAL LIABILITIES AND EQUITY 6 Nature of operations and going concern (Note 1) Subsequent events (Note 18) "Jack Fraser"   | \$                  |                 |
| Current Cash and cash equivalents Accounts receivable 5 Other receivable 12 Inventory 6 Prepaid expenses Total current assets 1 Intangible assets 8 4, Property and equipment 7 TOTAL ASSETS 6 ILABILITIES Current Accounts payable and accrued liabilities 12 1, Lease liability – current 9 Lease liability – current 9 Lease liability non-current 9 Lease liability non-current 9 Lease liability non-current 9 Lease liability non-current 9 CEBA loan 10 Note payable 10 CEBA loan 10 Note payable 10 Cenvertible debenture 10  SHAREHOLDERS' EQUITY 1 TOTAL LIABILITIES AND EQUITY 6 Vature of operations and going concern (Note 1) iubsequent events (Note 18) "Jack Fraser"  | Ş                   | •               |
| Cash and cash equivalents Accounts receivable 5 Other receivable 12 Inventory 6 Prepaid expenses Total current assets 1 Intangible assets 8 4 Property and equipment 7 TOTAL ASSETS 6 ILABILITIES Current Accounts payable and accrued liability – current 9 Lease liability – current 9 Lease liability non-current 9 Lease liability non-current 9 Lease liability non-current 9 SHAREHOLDERS' EQUITY Share capital 11 16 Reserve 11 22 Pricit 12 TOTAL LIABILITIES AND EQUITY 6 Vature of operations and going concern (Note 1) bubsequent events (Note 18) "Jack Fraser"   |                     |                 |
| Accounts receivable 5<br>Other receivable 12<br>Inventory 6<br>Prepaid expenses<br>Total current assets 1<br>Intangible assets 8<br>Property and equipment 7<br>TOTAL ASSETS 6<br>LIABILITIES<br>Current Accounts payable and accrued<br>liabilities 12 1<br>Lease liability – current 9<br>Due to Lexaria Canpharm ULC 8 & 10<br>CEBA loan 10<br>Note payable 10 1<br>Convertible debenture 10<br>Accounts Payable 10<br>Cereation 10<br>Note payable 10<br>Cereation 10<br>Note payable 10<br>Convertible debenture 10<br>Accounts Payable 10<br>Convertible Accounts Payable 10<br>Convertible A | 774,512             | 700,431         |
| Other receivable       12         Inventory       6         Prepaid expenses       1         Total current assets       1         Intangible assets       8       4         Property and equipment       7         TOTAL ASSETS       6         LIABILITIES       6         Current       7         Accounts payable and accrued       12         liabilities       12         Lease liability – current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11       16         Reserve       11       2         Deficit       (17,7)       7         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       5         uibsequent events (Note 18)       "Jack Fraser"   | 535,511             | 406,851         |
| Prepaid expenses       1         Intangible assets       8       4         Property and equipment       7       7         TOTAL ASSETS       6         LIABILITIES       6         Current       7         Accounts payable and accrued       1         liabilities       12       1         Lease liability – current       9       1         Lease liability non-current       9       1         CEBA loan       10       1         Note payable       10       1         Convertible debenture       10       4         SHAREHOLDERS' EQUITY       4       2         Deficit       (17,-       2         Deficit       (17,-       1         TOTAL LIABILITIES AND EQUITY       1       6         Vature of operations and going concern (Note 1)       5       6         Vature of operations and going concern (Note 1)       5       6         Vature of operations and going concern (Note 1)       5       6 <td< td=""><td>3,123</td><td>2,823</td></td<>   | 3,123               | 2,823           |
| Prepaid expenses       1         Total current assets       1         Intangible assets       8       4         Property and equipment       7         TOTAL ASSETS       6         LIABILITIES       6         Current       7         Accounts payable and accrued       1         liabilities       12       1         Lease liability – current       9       1         Lease liability non-current       9       1         Lease liability non-current       9       1         Lease liability non-current       9       1         CEBA loan       10       1         Note payable       10       1         Convertible debenture       10       4         SHAREHOLDERS' EQUITY       4       2         Deficit       (17,-       2         Deficit       (17,-       1         TOTAL SHAREHOLDERS' EQUITY       1       1         TOTAL LIABILITIES AND EQUITY       1       6         Vature of operations and going concern (Note 1)       5       6         Vature of operations and going concern (Note 1)       5       6         Vature of operations and going concern (Note 1) <t< td=""><td>139,067</td><td>193,912</td></t<>   | 139,067             | 193,912         |
| Total current assets       1         Intangible assets       8       4         Property and equipment       7         TOTAL ASSETS       6         LIABILITIES       6         Current       7         Accounts payable and accrued       1         liabilities       12       1         Lease liability – current       9         1       1         Lease liability non-current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         4       SHAREHOLDERS' EQUITY         Share capital       11         Reserve       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11         2       11 <tr< td=""><td>401,854</td><td>272,775</td></tr<>   | 401,854             | 272,775         |
| Property and equipment       7         TOTAL ASSETS       6         LIABILITIES       Current         Accounts payable and accrued       12         liabilities       12         Lease liability – current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11       16         Reserve       11       2         Deficit       (17,:       1         TOTAL SHAREHOLDERS' EQUITY       1       1         TOTAL LIABILITIES AND EQUITY       6       1         Subsequent events (Note 18)       "Jack Fraser"  | 1,854,067           | 1,576,793       |
| TOTAL ASSETS       6         LIABILITIES       Current         Accounts payable and accrued       liabilities         liabilities       12         Lease liability – current       9         Lease liability non-current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11         Reserve       11         Deficit       (17,-         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       5         Subsequent events (Note 18)       "Jack Fraser"   | 4,273,233           | 170,928         |
| LIABILITIES Current Accounts payable and accrued liabilities 12 1 Lease liability – current 9 Lease liability non-current 9 Due to Lexaria Canpharm ULC 8 & 10 CEBA loan 10 Note payable 10 1 Convertible debenture 10   SHAREHOLDERS' EQUITY Share capital 11 16 Reserve 11 2 Deficit (17,: TOTAL SHAREHOLDERS' EQUITY 1  TOTAL LIABILITIES AND EQUITY Subsequent events (Note 18) "Jack Fraser"  | 311,234             | 268,954         |
| Current Accounts payable and accrued liabilities 12 1 Lease liability – current 9 Lease liability non-current 9 Due to Lexaria Canpharm ULC 8 & 10 CEBA loan 10 Note payable 10 1 Convertible debenture 10  SHAREHOLDERS' EQUITY Share capital 11 16 Reserve 11 2 Deficit (17,: TOTAL SHAREHOLDERS' EQUITY 1  TOTAL LIABILITIES AND EQUITY 6 Nature of operations and going concern (Note 1) Subsequent events (Note 18)  "Jack Fraser"  | 6,438,534           | 2,016,673       |
| Accounts payable and accrued<br>liabilities 12 1,<br>Lease liability – current 9<br>Due to Lexaria Canpharm ULC 8 & 10<br>CEBA Ioan 10<br>Note payable 10 1,<br>Convertible debenture 10<br>SHAREHOLDERS' EQUITY<br>Share capital 11 16<br>Reserve 11 2<br>Deficit (17,5)<br>TOTAL SHAREHOLDERS' EQUITY 1<br>TOTAL LIABILITIES AND EQUITY 6<br>Nature of operations and going concern (Note 1)<br>Subsequent events (Note 18)<br>"Jack Fraser"   |                     |                 |
| liabilities       12       1,         Lease liability – current       9       1         Lease liability non-current       9       1         Due to Lexaria Canpharm ULC       8 & 10       6         CEBA loan       10       10         Note payable       10       1,         Convertible debenture       10       1,         Convertible debenture       10       4,         SHAREHOLDERS' EQUITY       4       4,         Share capital       11       16,         Reserve       11       2         Deficit       (17,4)       1         TOTAL SHAREHOLDERS' EQUITY       1,       1,         Nature of operations and going concern (Note 1)       5,       5,         Subsequent events (Note 18)       4,       5,  |                     |                 |
| liabilities       12       1         Lease liability – current       9         1       1         Lease liability non-current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11         Reserve       11         Deficit       (17,4)         TOTAL SHAREHOLDERS' EQUITY       1         Nature of operations and going concern (Note 1)       5         Subsequent events (Note 18)       "Jack Fraser"   |                     |                 |
| Lease liability – current       9         1       1         Lease liability non-current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11         Reserve       11         Deficit       (17,)         TOTAL SHAREHOLDERS' EQUITY       1         Nature of operations and going concern (Note 1)       6         Vature of operations and going concern (Note 1)       5         "Jack Fraser"   | 1,543,116           | 987,010         |
| 1         Lease liability non-current       9         Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         4       4         SHAREHOLDERS' EQUITY       4         Share capital       11       16         Reserve       11       2         Deficit       (17,1)       1         TOTAL SHAREHOLDERS' EQUITY       1       6         Nature of operations and going concern (Note 1)       5       5         Subsequent events (Note 18)       "Jack Fraser"   | 19,113              | 18,170          |
| Due to Lexaria Canpharm ULC       8 & 10         CEBA loan       10         Note payable       10         Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11         Reserve       11         Deficit       (17,1)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       5         Subsequent events (Note 18)       "Jack Fraser"   | 1,562,229           | 1,005,180       |
| CEBA loan10Note payable10Convertible debenture10SHAREHOLDERS' EQUITYShare capital11Reserve11Deficit(17,4)TOTAL SHAREHOLDERS' EQUITY1TOTAL SHAREHOLDERS' EQUITY1TOTAL LIABILITIES AND EQUITY6Nature of operations and going concern (Note 1)Subsequent events (Note 18)"Jack Fraser"  | 22,932              | 32,690          |
| Note payable       10       1,         Convertible debenture       10       4         SHAREHOLDERS' EQUITY       4         Share capital       11       16         Reserve       11       2         Deficit       (17,4)       1         TOTAL SHAREHOLDERS' EQUITY       1       1         TOTAL SHAREHOLDERS' EQUITY       1       6         Nature of operations and going concern (Note 1)       5       6         Wature of operations and going concern (Note 1)       5       6         Wature of operations and going concern (Note 1)       5       6         Wature of operations and going concern (Note 1)       5       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations and going concern (Note 1)       6       6         Wature of operations (Note 18)       6 <t< td=""><td>500,000</td><td></td></t<>   | 500,000             |                 |
| Convertible debenture       10         SHAREHOLDERS' EQUITY       4         Share capital       11       16         Reserve       11       2         Deficit       (17,5)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL SHAREHOLDERS' EQUITY       1         Mature of operations and going concern (Note 1)       6         Subsequent events (Note 18)       "Jack Fraser"  | 25,608              | 22,88           |
| SHAREHOLDERS' EQUITY         Share capital       11       16         Reserve       11       2         Deficit       (17,)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL SHAREHOLDERS' EQUITY       1         Nature of operations and going concern (Note 1)       6         Subsequent events (Note 18)       "Jack Fraser"  | 1,998,508           |                 |
| SHAREHOLDERS' EQUITY         Share capital       11       16         Reserve       11       2         Deficit       (17,1)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       5         Widsequent events (Note 18)       "Jack Fraser"   | 832,249             | 770,485         |
| Share capital       11       16         Reserve       11       2         Deficit       (17,)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       5         Subsequent events (Note 18)       "Jack Fraser"  | 4,941,526           | 1,831,246       |
| Reserve     11     2       Deficit     (17,5)       TOTAL SHAREHOLDERS' EQUITY     1       TOTAL LIABILITIES AND EQUITY     6       Nature of operations and going concern (Note 1)     6       Subsequent events (Note 18)     "Jack Fraser"  |                     |                 |
| Deficit       (17,4)         TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       6         Subsequent events (Note 18)       "Jack Fraser"   | 16,039,248          | 13,844,029      |
| TOTAL SHAREHOLDERS' EQUITY       1         TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       6         Subsequent events (Note 18)       "Jack Fraser"  | 2,973,540           | 2,900,803       |
| TOTAL LIABILITIES AND EQUITY       6         Nature of operations and going concern (Note 1)       6         Subsequent events (Note 18)       6         "Jack Fraser"       6   | (17,515,780)        | (16,559,405     |
| Nature of operations and going concern (Note 1)<br>Subsequent events (Note 18)<br>"Jack Fraser"  | 1,497,008           | 185,42          |
| Subsequent events (Note 18)<br>"Jack Fraser"   | 6,438,534           | 2,016,673       |
| "Jack Fraser"  |                     |                 |
|  |                     |                 |
| Director   | "Craig E            | inkley"         |
|  | Dire                | ctor            |

The accompanying notes are an integral part of these condensed interim consolidated financial statements

# Hill Street Beverage Company Inc.

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss

(Expressed in Canadian Dollars)

|  |       | Three Months Ended |             | Six Montl    | hs Ended    |
|--|-------|--------------------|-------------|--------------|-------------|
|  |       | December           | December    | December     | December    |
|  |       | 31,                | 31,         | 31,          | 31,         |
|  | Notes | 2020               | 2019        | 2020         | 2019        |
|  |       | \$                 | \$          | \$           | \$          |
| Gross Revenue  | 6/15  | 875,529            | 973,710     | 1,259,979    | 1,487,476   |
| Chargebacks & listing fees                           | 6     | (129,780)          | (284,434)   | (239,518)    | (468,761)   |
| Net Revenue  |       | 745,749            | 689,276     | 1,020,461    | 1,018,715   |
| Direct Costs   |       | (363,840)          | (395,228)   | (492,546)    | (547,264)   |
| Gross profit   |       | 381,909            | 294,048     | 527,915      | 471,451     |
| Expenses   |       |                    |             |              |             |
| Accretion expense                                    | 10    | 32,440             | -           | 64,234       | -           |
| Bank charges and interest                            |       | 22,186             | 462         | 24,569       | 1,446       |
| Consulting fees                                      |       | 7,503              | -           | 15,332       | -           |
| Depreciation   | 9/10  | 31,211             | 23,307      | 59,132       | 47,851      |
| Donations, dues & licenses                           |       | (8,704)            | 30,941      | (2,222)      | 189,477     |
| Filing and transfer agent fees                       |       | 20,414             | 21,973      | 38,052       | 38,389      |
| Interest on convertible loan                         | 10    | 15,464             | -           | 30,928       | -           |
| Management fees                                      | 12    | 15,000             | 22,000      | 30,000       | 30,000      |
| Marketing  |       | 76,560             | 72,732      | 133,992      | 236,998     |
| Office and miscellaneous                             |       | 44,337             | 15,802      | 63,590       | 31,729      |
| Professional fees                                    |       | 156,088            | 273,436     | 212,200      | 1,060,428   |
| Stock-based compensation                             | 11/12 | 28,624             | 84,294      | 75,243       | 214,732     |
| Travel and meal allowance                            |       | 7,378              | 12,321      | 7,914        | 40,450      |
| Wages and salaries                                   | 12/13 | 233,315            | 398,331     | 437,454      | 644,238     |
| Selling and delivery                                 |       | 183,878            | 196,208     | 297,117      | 319,059     |
|  |       | (865,694)          | (1,151,807) | (1,487,535)  | (2,854,797) |
|  |       | (2,407)            | (1 422)     | (1.080)      | (12 757)    |
| Foreign exchange gain (loss)                         |       | (3,497)            | (1,433)     | (1,980)      | (13,757)    |
| Gain on settlement of liability                      |       | 6,730              | -           | 6,730        | -           |
| Write-off of intangibles<br>Write-off of inventory   | c     | -                  | (22.466)    | -<br>(1 525) | (8,000)     |
| ,  | 6     | -                  | (23,466)    | (1,535)      | (23,466)    |
| Other income   |       | 30                 | - (24.800)  | 30           | (45.222)    |
| Loss and comprehensive loss for the                  |       | 3,263              | (24,899)    | 3,245        | (45,223)    |
| Loss and comprehensive loss for the period           |       | (480,522)          | (882,658)   | (956,375)    | (2,428,569) |
|  |       |                    |             |              |             |
| Basic and diluted loss per common share              | _     | (0.00)             | (0.01)      | (0.01)       | (0.02)      |
| Weighted average number of common shares outstanding |       | 122,399,917        | 98,754,081  | 117,289,721  | 97,858,706  |

# Hill Street Beverage Company Inc. Condensed Interim Consolidated Statements of Changes in Equity

(Expressed in Canadian Dollars)

|  | Common      | Shares          |              |           |              |             |
|--|-------------|-----------------|--------------|-----------|--------------|-------------|
|  |             |                 | Shares to be |           |              |             |
|  | Shares      | Amount          | issued       | Reserve   | Deficit      | Total       |
|  |             | \$              | \$           | \$        | \$           | \$          |
| As at June 30, 2019                          | 96,283,331  | 12,938,115      | -            | 2,317,379 | (12,877,726) | 2,377,768   |
| Units issued for cash (Note 11)              | 8,666,665   | 436,235         | -            | 83,765    | -            | 520,000     |
| Units issued for services (Note 11)          | 4,658,333   | 234,476         |              | 45,024    |              | 279,500     |
| Share issuance costs                         | -           | (52,780)        | -            | -         | -            | (52,780)    |
| Exercise of stock options (Note 11)          | 680,000     | 169,200         | -            | (91,000)  | -            | 78,200      |
| Exercise of warrants (Note 11)               | 187,250     | 59 <i>,</i> 350 | -            | (21,900)  | -            | 37,450      |
| Stock-based compensation                     | -           | -               | -            | 214,732   | -            | 214,732     |
| Net loss for the period                      | -           | -               | -            | -         | (2,428,569)  | (2,428,569) |
| As at December 31, 2019                      | 110,475,579 | 13,784,596      | -            | 2,548,000 | (15,306,295) | 1,026,301   |
| Share issuance costs                         | -           | (24,134)        | -            | -         | -            | (24,134)    |
| Shares issued for debt (Note 11)             | 1,584,801   | 83,567          | -            | -         | -            | 83,567      |
| Convertible debenture warrants               | -           | -               | -            | 136,130   | -            | 136,130     |
| Conversion feature - reserve                 | -           | -               | -            | 136,130   | -            | 136,130     |
| Stock-based compensation                     | -           | -               | -            | 80,543    | -            | 80,543      |
| Net loss for the period                      | -           | -               | -            | -         | (1,253,110)  | (1,253,110) |
| As at June 30, 2020                          | 112,060,380 | 13,844,029      | -            | 2,900,803 | (16,559,405) | 185,427     |
| Shares issued for debt                       | 144,229     | 12,259          | -            | -         | -            | 12,259      |
| Units issued for cash (Note 11)              | 17,019,000  | 576,369         | -            | 274,581   | -            | 850,950     |
| Share issuance costs                         | -           | (20,933)        | -            | -         | -            | (20,933)    |
| Units issued pursuant to licensing (Note 11) | 6,031,363   | 753,920         | -            | -         | -            | 753,920     |
| Exercise of warrants (Note 11)               | 6,465,178   | 873,604         | -            | (277,087) | -            | 596,517     |
| Stock-based compensation                     | -           | -               | -            | 75,243    | -            | 75,243      |
| Net loss for the period                      | -           | -               | -            | -         | (956,375)    | (956,375)   |
| As at December 31, 2020                      | 141,720,150 | 16,039,248      | -            | 2,973,540 | (17,515,780) | 1,497,008   |

The accompanying notes are an integral part of these condensed interim consolidated financial statements

# Hill Street Beverage Company Inc.

# **Condensed Interim Consolidated Statements of Cash Flows**

(Expressed in Canadian Dollars)

| For the Six-Month Period Ended                  | December 31, 2020 | December 31, 2019 |
|---|-------------------|-------------------|
|   | \$                | \$                |
| OPERATING ACTIVITIES                            |                   |                   |
| Net loss  | (956,375)         | (2,428,569)       |
| Items not affecting cash:                       | E0 133            | 47.051            |
| Depreciation<br>Write-off of inventory          | 59,132            | 47,851            |
| Write-off of intangibles                        | 1,535             | 23,466<br>8,000   |
| Shares issued for professional fees             |                   | 279,500           |
| Stock based compensation                        | 75,243            | 214,732           |
| Accretion expense                               | 64,234            | -                 |
| Accrued interest                                | 44,755            | -                 |
|   | (711,476)         | (1,855,020)       |
| Changes in non-cash working capital items:      | (, 11), (, 0)     | (1)000)020)       |
| Accounts receivable                             | (122,510)         | (81,122)          |
| Inventory                                       | 53,309            | (39,672)          |
| Prepaid expenses                                | (151,198)         | 132,997           |
| Accounts payable and accrued liabilities        | (38,981)          | 584,150           |
| Other receivable                                | (300)             | -                 |
|   |                   |                   |
| Cash used in operating activities               | (971,156)         | (1,258,667)       |
| INVESTING ACTIVITIES                            |                   |                   |
| Purchase of equipment                           | (4,713)           | (3,255)           |
| Purchase of intangible assets                   | (359,840)         | (-)               |
|   |                   |                   |
| Cash used in investing activities               | (364,553)         | (3,255)           |
| FINANCING ACTIVITIES                            |                   |                   |
| Shares issued net of costs                      | 823,866           | 467,220           |
| Proceeds from exercise of options               |                   | 78,200            |
| Proceeds from exercise of warrants              | 596,518           |                   |
| Lease payments                                  | (10,594)          | -                 |
| Repayment of loans                              | (,,,              | -                 |
| Advances to related parties                     | -                 | 30,000            |
| Cash provided by financing activities           | 1,409,790         | 575,420           |
| CHANGE IN CASH AND CASH EQUIVALENTS             | 74,081            | (686,502)         |
| CASH AND CASH EQUIVALENTS, BEGINNING<br>OF YEAR | 700,431           | 1,068,612         |
| CASH AND CASH EQUIVALENTS, END OF PERIOD        | 774,512           | 382,110           |

Supplementary cash flow information (Note 17)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

#### 1. NATURE OF OPERATIONS AND GOING CONCERN

Hill Street Beverage Company Inc., formerly Avanco Capital Corp. (the "Company") was incorporated on April 6, 2016 in British Columbia under the Business Corporations Act (British Columbia) and was continued to Ontario under the Business Corporations Act (Ontario) on November 30, 2018. The Company commenced trading on the TSX Venture Exchange (the "TSX V") under the symbol "AAA.P" on March 24, 2017. The Company is engaged in supplying alcohol free drinks. The Company sells its products online, in retail stores and to distributors in Canada.

The Company changed its name from Avanco Capital Corp. to Hill Street Beverage Company Inc. on July 24, 2018 in conjunction with a reverse takeover transaction (the "RTO"). The Company resumed trading on the TSX V at the opening of the market on July 24, 2018 under the new symbol "BEER".

The Company's registered address and the records are held at 480 University Ave. Suite 1401, Toronto, Ontario, M5G 1V2.

Effective July 24, 2018, the Company completed a consolidation of its common shares ("share consolidation") on the basis of 65.358 post-consolidation shares for every pre-consolidation common share previously held. All references to share, per share amounts and exercise prices have been retroactively restated to reflect the effect of the share consolidation.

These condensed interim consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future and that management does not intend to liquidate the entity, or has no realistic alternative but to do so. As at December 31, 2020, the Company had not yet achieved profitable operations, had a net loss of \$956,375 (December 31, 2019: \$2,428,569), a deficit of \$17,515,780 (June 30, 2020: \$16,559,405), and expects to incur further losses in the foreseeable future, all of which indicate the existence of a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern. Realization values may be substantially different from carrying values as shown and these consolidated financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. Such adjustments could be material.

The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon its ability to obtain necessary financing and generate operational profit to meet its ongoing levels of corporate overhead and discharge its liabilities as they come due. The success of the Company's endeavors cannot be predicted at this time. There is no assurance that it will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company.

#### 1. NATURE OF OPERATIONS AND GOING CONCERN (continued)

During the period, the global outbreak of COVID-19 (coronavirus) continued, which has had an impact on businesses through the restrictions put in place by the Canadian, provincial and municipal governments regarding travel, business operations and isolation/quarantine orders. The Company's operations were impacted by COVID-19 due to a slower growth in year over year sales than anticipated. At this time, it is unknown the extent of the impact the COVID-19 outbreak may have on the Company as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put, in place by Canada and other countries to fight the virus. While the extent of the impact is unknown, we anticipate this outbreak may cause reduced customer demand, supply chain disruptions, staff shortages, and increased government regulations, all of which may negatively impact the Company's business and financial condition.

#### 2. BASIS OF PREPARATION

#### Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") and IAS 34 – Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). As such, these interim financial statements do not contain all the disclosures required by IFRS for annual financial statements and should be read in conjunction with the Company's audited annual consolidated financial statements for the years ended June 30, 2020 and 2019 (the "Annual Financial Statements").

#### **Basis of Presentation**

The condensed interim consolidated financial statements have been prepared on a historical cost basis except for certain financial assets that are measured at fair value. All dollar amounts presented are in Canadian dollars unless otherwise specified.

#### **Consolidation**

These condensed interim consolidated financial statements incorporate the financial statements of the Company and its wholly owned subsidiaries, Hill Street Marketing Inc. and Hill Avenue Cannabis Inc., companies incorporated in Ontario. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are included in the consolidated financial statements from the date control is obtained until the date control ceases. All significant intercompany transactions and balances have been eliminated.

#### 3. SIGNIFICANT ACCOUNTING POLICIES

#### **Accounting Policies**

Effective December 9, 2019, the Company changed the useful life over which depreciation expense is record on its licenses from 5 years to 10 years using the straight-line method. The change in estimate has been applied prospectively. This change in estimate is based upon the amended agreement entered with Lexaria Canpharm ULC. (Note 8).

#### 4. NET REVENUE

| For the six-month period ended | December 31, 2020 | December 31, 2019 |
|--------------------------------|-------------------|-------------------|
| Gross revenue                  | \$<br>1,259,979   | 1,487,476         |
| Chargebacks                    | (239,518)         | (444,761)         |
| Listing fees                   | -                 | (24,000)          |
|                                | \$<br>1,020,461   | 1,018,715         |

#### 5. ACCOUNTS RECEIVABLE

Accounts receivable consist of the following:

| As at                   | December 31, 2020 | June 30, 2020 |
|-------------------------|-------------------|---------------|
| Trade receivables       | \$<br>514,040     | 406,851       |
| GST receivables         | 15,321            | -             |
| Subscription receivable | 6,150             | -             |
|                         | \$<br>535,511     | 406,851       |

An allowance for doubtful accounts of \$Nil (June 30, 2020: \$Nil) has been provided against these accounts receivable amounts, which the Company has determined represents a reasonable estimate of amounts that may be uncollectible.

#### 6. INVENTORY

| As at          | December 31, 2020 | June 30, 2020 |
|----------------|-------------------|---------------|
| Finished goods | \$<br>139,067     | 193,911       |

Inventory write downs recognized as an expense amounted to \$1,535 (December 31, 2019: \$Nil).

#### 7. PROPERTY AND EQUIPMENT

|  | ROU<br>Asset | Computer<br>Equipment | Computer<br>Software | Equipment | Asset<br>development<br>(i) | Total   |
|--|--------------|-----------------------|----------------------|-----------|-----------------------------|---------|
| Cost   | \$           | \$                    | \$                   | \$        | \$                          | \$      |
| Balance at June 30, 2019                             | -            | 6,104                 | 1,544                | 277,184   | -                           | 284,832 |
| Additions  | 53,019       | 901                   | 443                  | 455       | -                           | 54,818  |
| Balance at June 30, 2020                             | 53,019       | 7,005                 | 1,987                | 277,639   | -                           | 339,650 |
| Additions  | -            | 1,589                 | 123                  | -         | 71,931                      | 73,643  |
| Balance at December 31, 2020                         | 53,019       | 8,594                 | 2,110                | 277,639   | 71,931                      | 413,293 |
| Accumulated depreciation<br>Balance at June 30, 2019 | -            | 2,897                 | 1,219                | 4,921     | -                           | 9,037   |
| Depreciation for the year                            | 5,891        | 1,069                 | 236                  | 54,463    | -                           | 61,659  |
| Balance at June 30, 2020                             | 5,891        | 3,966                 | 1,455                | 59,384    | -                           | 70,696  |
| Depreciation for the period                          | 8,837        | 606                   | 94                   | 21,826    | -                           | 31,363  |
| Balance at December 31, 2020                         | 14,728       | 4,572                 | 1,549                | 81,210    | -                           | 102,059 |
| Carrying amount<br>at June 30, 2020                  | 47,128       | 3,039                 | 532                  | 218,255   | -                           | 268,954 |
| Carrying amount<br>at December 31, 2020              | 38,291       | 4,022                 | 561                  | 196,429   | 71,931                      | 311,234 |

(i) The Company capitalized cost related of implementation of cloud computing arrangements that qualify for capitalization. Such capitalized costs are amortized using the straight-linemethod over the term of the cloud computing service contract, beginning when the cloud computing arrangement is substantially complete and ready for its intended used. During the six-month period ended July 31, 2020, there were \$71,931 and the Company's estimate the implementation of the asset will be completed by June 30, 2021.

#### 8. INTANGIBLE ASSETS

|                              | Canpharm     | Canpharm       | Standard     |            |           |
|------------------------------|--------------|----------------|--------------|------------|-----------|
|                              | License (i)- | License (ii) – | Processor    |            |           |
|                              | Finite       | Infinite       | License (ii) | Trademarks | Total     |
|                              |              |                |              |            |           |
| Cost                         | \$           |                |              |            |           |
| Balance at June 30, 2019     | 209,250      | -              | 59,250       | -          | 268,500   |
| Additions                    | -            | -              | -            | 7,698      | 7,698     |
| Write-offs                   | -            | -              | (8,000)      |            | (8,000)   |
| Balance at June 30, 2020     | 209,250      | -              | 51,250       | 7,698      | 268,198   |
| Additions                    | 425,346      | 3,694,888      | -            | 9,840      | 4,130,074 |
| Balance at December 31, 2020 | 634,596      | 3,694,888      | 51,250       | 17,538     | 4,398,272 |
|                              |              |                |              |            |           |
| Accumulated depreciation     |              |                |              |            |           |
| Balance at June 30, 2019     | 38,329       | -              | 8,362        | -          | 46,691    |
| Depreciation for the year    | 42,002       | -              | 8,577        | -          | 50,579    |
| Balance at June 30, 2020     | 80,331       | -              | 16,939       | -          | 97,270    |
| Depreciation for the period  | 24,338       | -              | 3,431        | -          | 27,769    |
| Balance at December 31, 2020 | 104,669      | -              | 20,370       | -          | 125,039   |
|                              |              |                |              |            |           |
| Carrying amount              |              |                |              |            |           |
| at June 30, 2020             | 128,919      | -              | 34,311       | 7,698      | 170,928   |
|                              |              |                |              |            |           |
| Carrying amount              |              |                |              |            |           |
| at December 31, 2020         | 529,927      | 3,694,888      | 30,880       | 17,538     | 4,273,233 |

(i) On July 30, 2018, the Company entered into a semi-exclusive licensing agreement with Lexaria Bioscience Corp. for the use of its technology to produce a line of cannabis-infused alcoholfree beverages for Canadian distribution, following regulatory approval. The Company was required to pay a licensing fee of USD\$93,750 payable over 274 days and an initial share issuance equal to USD\$56,250. As of June 30, 2019, all amounts have been paid and the Company has capitalized a total of \$209,250 related to this agreement. These licenses fees are being amortized over their useful life of five years (the effective term of the license agreement).

On December 9, 2020, the Company entered into an intellectual property license agreement with Lexaria HempCo. to expand the Company's license with Lexaria HempCo to make products containing CBD on a global basis for ten years. This agreement hereby supersedes and replaces in its entirety the prior agreement dated July 30, 2018. The Company changed the useful life over which depreciation expense is recorded on its licenses from 5 to 10 years.

#### 8. INTANGIBLE ASSETS (continued)

(ii) On December 9, 2020, the Company entered into an asset purchase agreement with Lexaria Canpharm ULC. to acquire exclusive rights in perpetuity to use Lexaria's non-pharmaceutical THC-related intellectual property assets and license agreement assets to produce and/or license cannabis-infused products globally. The Company is required to pay \$350,000 (paid) in cash on closing, an additional \$2,000,000 payable over time in the form of a promissory note bearing 10% interest per annum and \$1,500,000 in common shares of the Company, issuable in three equal tranches of \$500,000 at closing; \$500,000 eight months after closing; and \$500,000 16 months after closing. The license agreements assets acquired with finite life are being amortized over their useful life of 10 years (the effective term of the asset purchase agreement).

The following table summarizes the price allocation:

| Assets Acquired                       |              |
|---------------------------------------|--------------|
| Prepaid                               | \$<br>22,341 |
| Canpharm – finite life                | 425,346      |
| Canpharm – infinite life              | 3,694,888    |
|                                       | 4,142,575    |
| Consideration                         |              |
| Fair value of 6,031,363 common shares | 753,920      |
| Contingent consideration              | 1,000,000    |
| Promissory note                       | 2,000,000    |
| Cash                                  | 350,000      |
| Transactions cost                     | 38,655       |
| Total Consideration                   | 4,142,575    |

(iii) As of June 30, 2019, the Company has capitalized a total of \$59,250 of costs associated with acquiring a Standard Processor License in the Cannabis act (Canada). These licenses fees are being amortized over their useful life of 5 years.

(iv) As of December 31, 2020, the Company has capitalized a total of \$17,538 for trademarks. The trademark is not amortized as the trademark is not yet in use.

#### 9. LEASES

The Company has a lease for industrial commercial space. The Company's lease commenced on February 25, 2020 and extends to February 28, 2023. The Company has an option to extend the lease beyond the three-year non-cancellable term for an additional term of three years. The Company has recognized a right-of-use asset in respect of this lease, which is included in property and equipment on the consolidated statements of financial position (Note 7).

The Company has also recognized a lease liability for this lease, which was initially measured at the present value of the future lease payments, discounted using the Company's incremental borrowing rate of 6%. Interest expense on the lease liability is included in Bank charges and Interest in the consolidated statements of operations and comprehensive loss. The carrying amount of the Company's lease liability is summarized in the table below.

|                            | Lease liability |
|----------------------------|-----------------|
| Balance, June 30, 2019     | -               |
| Additions                  | 53,019          |
| Interest expense           | 1,378           |
| Lease payments             | (3,531)         |
| Balance, June 30, 2020     | 50,866          |
| Interest expense           | 1,773           |
| Lease payments             | (10,594)        |
| Balance, December 31, 2020 | 42,045          |
| Current portion            | 19,113          |
| Non-current portion        | 22,932          |

#### **10. LOANS PAYABLE**

The Company has the following loans payable as at December 31, 2020 and June 30, 2020:

| As at                                | December 31, 2020 | June 30, 2020 |
|--------------------------------------|-------------------|---------------|
|                                      | \$                | \$            |
| CEBA loan                            | 25,608            | 22,885        |
| Convertible debenture                | 832,249           | 770,485       |
| Due to Lexaria Canpharm ULC (Note 8) | 500,000           | -             |
| Note payable                         | 1,998,508         | -             |
|                                      |                   |               |
| Total long term debt                 | 3,356,365         | 793,370       |

# Hill Street Beverage Company Inc. Notes to the Condensed Interim Consolidated Financial Statements For the Three and Six Months Period Ended December 31, 2020 and 2019 (Expressed in Canadian Dollars)

#### **10. LOANS PAYABLE (continued)**

Canada Emergency Business Account

|                                      | CEBA loan  |
|--------------------------------------|------------|
| Proceeds                             | \$40,000   |
| Benefit from favorable interest rate | (\$17,939) |
| Initial carrying amount              | \$22,061   |
| Accretion Expense                    | \$824      |
| Balance at June 30, 2020             | \$22,885   |
| Accretion Expense                    | \$2,723    |
| Balance at December 31, 2020         | \$25,608   |

On May 1, 2020, the Company received a loan of \$40,000 pursuant to the Canada Emergency Business Account ("CEBA"). The CEBA provides zero-interest, partially forgivable loans of up to \$40,000 to small businesses that have experienced diminished revenues due to COVID-19 but face ongoing non-deferrable costs, such as rent, utilities, insurance, taxes and employment costs. If the balance of the loan is repaid on or before December 31, 2022, 25% of the loan will be forgiven. The loan bears no interest until December 31, 2022, at which point if unpaid, it will convert to a three-year term loan bearing interest at 5% per annum. The loan was initially measured at its fair value of \$22,061 and is subsequently measured at amortized cost, using an effective interest rate of 23%. During the six-month period ended December 31, 2020, \$2,723 (December 31, 2019: \$Nil) of interest expense related to the CEBA loan was recognized and included in accretion expense in the consolidated statements of operations and comprehensive loss.

The Company received a benefit of \$17,939 due to the below-market interest rate on the CEBA loan. This benefit was initially recognized as a deferred gain and was recognized as income as the Company used the proceeds from the loan to fund its operational expenditures.

| Proceeds  | \$1,022,500 |
|---|-------------|
| Transaction costs                                 | (\$8,500)   |
| Net proceeds                                      | \$1,014,000 |
| Conversion feature                                | (\$136,130) |
| Warrants  | (\$136,130) |
| Debenture liability                               | \$741,740   |
|   |             |
| Initial measurement of debenture liability        | \$741,740   |
| Interest Expense                                  | \$10,085    |
| Accretion Expense                                 | \$18,660    |
| Balance, June 30, 2020                            | \$770,485   |
| Interest Expense                                  | \$30,927    |
| Accretion Expense                                 | \$61,511    |
| Interest payment reclassified to accounts payable | (\$30,674)  |
| Balance, December 31, 2020                        | \$832,249   |

#### Convertible debenture

# **10. LOANS PAYABLE (continued)**

Convertible debenture (continued)

On May 1, 2020, the Company issued \$1,022,500 principal amount of convertible debenture units. Each unit is comprised of \$1.00 principal amount of secured convertible debentures and 20 common share purchase warrants. Each warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.05 per share for a period of two years from the date of issuance. The convertible debentures bear interest at 6% per annum, payable semi-annually on November 1 and May 1 in each year.

The outstanding principal and any accrued and unpaid interest may, at the option of the holder, be converted at any time prior to maturity into common shares in the capital of the Company at a conversion price of \$0.05 per share for the first year of the term and \$0.10 thereafter. The principal subscribers in the financing were the Company's CEO and HoldCo St. Catharines Ltd., the Company's largest shareholder.

The loan was initially measured at its fair value of \$741,740, calculated by discounting the future cash flows using a market interest rate of 25%. The loan is subsequently measured at amortized cost using the effective interest method, at an effective interest rate of 23%. During the six-month period ended December 31, 2020, the Company recognized \$30,927 (December 31, 2019: \$Nil) in interest expense and \$61,511 (December 31, 2019: \$Nil) in non-cash accretion expense, which are included in the consolidated statements of operations and comprehensive loss.

At issuance, the equity component of the convertible debenture was measured at \$272,260. The equity component was allocated between the conversion feature and warrants based on their relative fair values, measured using the Black-Scholes option pricing model. A value of \$136,130 was assigned to both the conversion feature and the warrants, both of which are included in reserves on the consolidated statements of financial position. Significant assumptions used to value the conversion feature and attached warrants are presented in the following table.

| Stock Price    | \$0.045 |
|----------------|---------|
| Exercise Price | \$0.05  |
| Expected life  | 2 years |
| Volatility     | 93%     |
| Dividends      | \$0     |
| Risk-free rate | 0.37%   |

#### Promissory note

On December 9, 2020, in consideration of the value received in connection with purchase asset agreement entered with Lexaria Canpharm ULC, the Company promised to pay the principal sum of \$2,000,000. The principal amount shall bear interest at the rate of 10% per annum and shall accrue and be calculated quarterly-annually. The principal amount and any accrued interest shall be repayable by the Company in quarterly installments in an amount equal to 5% of the Gross Sales realized from cannabis infused product sold by the Company or its licenses utilizing the acquired technology. During the six-month period ended December 31, 2020, the Company recognized \$12,055 (December 31, 2020; \$Nil) in interest expenses. As at December 31, 2020, the Company reclassified a principal repayment of \$1,492 to accounts payable.

#### 11. SHARE CAPITAL

a) Authorized

Unlimited number of common shares with no par value.

#### b) Issued and outstanding

At December 31, 2020 and June 30, 2020, the issued and outstanding share capital is comprised of 141,720,150 and 112,060,380 common shares, respectively.

#### During the period ended December 31, 2020 the Company issued the following shares:

On September 14, 2020, the Company issued 144,229 shares in lieu of severance obligations to a former senior officer valued at \$12,259. A provision of \$12,259 was included in accounts payable and accrued liabilities on the consolidated statements of financial position as at June 30, 2020.

On November 18, 2020, the Company issued 17,019,000 units at a price of \$0.05 per unit for gross proceeds of \$850,950. Each unit consisted of one common share and one common share purchase warrant, with each whole warrant exercisable into one common share of the Company at an exercise price of \$0.13 per share, exercisable for a period of 24 months from the date of issuance. The warrants were assigned a value of \$274,581. In connection to the private placement, the Company paid \$20,933 in cash for share issuance cost.

On December 9, 2020, the Company issued 6,031,363 units valued to \$753,920 pursuant to licensing agreement entered with Lexaria Canpharm ULC. (Note 8).

The Company issued 6,465,178 shares for the exercise of warrants for gross proceeds of \$596,517. The shares issued were valued at 873,604, representing the sum of the proceeds of \$596,517 and the transfer of previously recognized warrants reserve of \$277,087.

#### During the year ended June 30, 2020 the Company issued the following shares:

On December 19, 2019, the Company issued 13,324,998 units at a price of \$0.06 per unit. Each unit consisted of one common share and one common share purchase warrant, with each whole warrant exercisable into one common share of the Company at an exercise price of \$0.13 per share, exercisable for a period of 24 months from the date of issuance. The December 19, 2019 issuance of units is split into two components:

1) The Company issued 8,666,665 units for cash proceeds as part of a private placement. Proceeds of \$520,000 were allocated as follows: \$436,235 to share capital and \$83,765 to warrant reserves. The Company paid \$76,914 in transaction costs in connection with the private placement.

- b) Issued and outstanding
  - 2) The Company issued 4,658,333 units for services valued at \$279,500. The Company allocated \$234,476 to share capital and \$45,024 to warrant reserves.

On May 4, 2020, the Company issued 1,584,801 shares in lieu of severance obligations to former senior officers valued at \$126,784. The shares issued were valued at \$83,567 and a \$43,217 gain on settlement was recorded in the consolidated statements of operations and comprehensive loss. A provision of \$12,259 has also been recorded for the contingent payment of 144,229 shares in connection with the settlement of severance obligations. The provision is included in accounts payable and accrued liabilities on the consolidated statements of financial position.

The Company issued 680,000 shares for the exercise of options for gross proceeds of \$78,200. The shares issued were valued at \$169,200, representing the sum of the proceeds of \$78,200 and the transfer of previously recognized option reserves of \$91,000.

The Company issued 187,250 shares for the exercise of warrants, with the exercise price of \$37,450, settled by offsetting against an amount payable to the exercising party. The shares issued were valued at \$59,350, representing the sum of the exercise price of \$37,450 and the transfer of previously recognized warrant reserves of \$21,900.

| Granted       | Expiry           |        | Exercise<br>Price | June 30, 2020   | Granted   | Expired /<br>Forfeited | Dec. 31,<br>2020 | Exercisa | able |
|---------------|------------------|--------|-------------------|-----------------|-----------|------------------------|------------------|----------|------|
|               |                  |        |                   | ,               |           |                        |                  |          |      |
| July 31, 2018 | July 31, 2023    | \$     | 0.175             | 6,564,314       | -         | (2,007,571)            | 4,556,743        | 3,417,5  | 557  |
| Jan. 31, 2020 | Jan. 31, 2021    | \$     | 0.175             | 518,027         |           | -                      | 518,027          | 518,0    | )27  |
| July 24, 2020 | Dec 31, 2021     | \$     | 0.175             | -               | 1,036,054 | -                      | 1,036,054        | 1,036,0  | )54  |
| Dec. 17, 2020 | Dec. 27, 2021    | \$     | 0.175             | -               | 63,750    | -                      | 63,750           | 63,7     | 750  |
| May 23, 2019  | May 23, 2024     | \$     | 0.21              | 215,000         | -         | -                      | 215,000          | 107,5    | 500  |
| May 1, 2020   | May 1, 2025      | \$     | 0.05              | 3,740,000       | -         | (300,000)              | 3,440,000        | 860,0    | 000  |
| Dec. 17, 2020 | Dec. 17, 2021    | \$     | 0.05              | -               | 75,000    |                        | 75,000           | 75,0     | )00  |
|               | Total            |        |                   | 11,037,341      | 1,174,804 | (2,307,571)            | 9,904,574        | 6,077,8  | 388  |
|               |                  |        |                   |                 |           |                        |                  |          |      |
|               | Weighted average | ge exe | ercise pric       | e               | \$ 0.17   | \$ 0.16                | \$ 0.13          | \$0      | .16  |
|               | Weighted average | ge rer | naining co        | ontractual life |           |                        | 2.89 years       |          |      |

## c) Stock options

The continuity of options for the period ended December 31, 2020 is summarized below:

During the six-month period ended December 31, 2020, 1,036,054 options held by a former Officer of the Company, previously granted on July 31, 2018, were vested immediately during the period and the expected life were reduced to December 31, 2021. \$4,712 was recorded as result of the modification of the award.

c) Stock options (continued)

#### During the year ended June 30, 2020 the Company granted the following stock options:

On May 1, 2020, 3,740,000 options were granted to officers, directors, and consultants at an exercise price of \$0.05 per share. The options shall vest equally 12.50% quarterly over a two-year term. The fair value of the options at grant date was \$122,100, of which \$39,477 (December 31, 2019: \$Nil) was recorded during the six-month period ended December 31, 2020 based on the vesting terms. A total of 225,000 of unvested options were forfeited during the periods ended December 31, 2020. Previously recorded stock-based compensation of \$3,954 (December 31, 2019: \$Nil) related to the forfeited options was reversed during the six-month period ended December 31, 2020.

#### During the year ended June 30, 2019 the Company granted the following stock options:

On July 31, 2018, 7,934,510 options were granted to officers and directors at an exercise price of \$0.175 per share. The options shall vest equally 8.33% quarterly over a three-year term. The fair value of the options at grant date was \$1,289,012, of which \$57,073 (December 31, 2019: \$175,018) was recorded in the three-month period ended December 31, 2020 based on vesting periods. A total of 21,250 and 842,169 of unvested options were forfeited during the periods ended December 31, 2020 and June 30, 2020. Previously recorded stock-based compensation of \$25,621 (December 31, 2019: \$Nil) related to the forfeited options was reversed during the six-month period ended December 31, 2020.

On May 23, 2019, 215,000 options were granted to officers and directors at an exercise price of \$0.21 per share. The options shall vest equally 8.33% quarterly over a three-year term. The fair value of the options at grant date was \$33,699, of which \$3,556 (December 31, 2019: \$12,019) was recorded in the three-month period ended December 31, 2020 based on vesting periods.

On May 13, 2019, the expected life of 10,000 fully vested options held by a former employee of the Company, previously granted on July 31, 2018, were reduced to one year from the date of employee's death and a total of 50,000 of unvested options were cancelled during the year ended June 30, 2019. An additional stock-based compensation was recorded in the amount of \$2,213 as a result of the modification of the award.

On July 17, 2019, 690,702 options held by a former employee of the Company, previously granted on July 31, 2018, were vested immediately during the period and the expected life were reduced to one year from the date of employment termination. An additional stock-based compensation was recorded in the amount of \$25,482 as a result of the modification of the award.

d) Stock options (continued)

The following weighted average assumptions were used in the option pricing models of stock options granted during the years ended June 30, 2020 and 2019:

|                         | June 30, 2020 | June 30, 2019 |
|-------------------------|---------------|---------------|
| Share price             | \$0.045       | \$0.15        |
| Risk-free interest rate | 0.43%         | 2.25%         |
| Expected life           | 5 years       | 8.67 years    |
| Expected volatility     | 100%          | 100%          |
| Expected dividends      | Nil           | Nil           |

Volatility is based on peer companies. Expected life is considered to be the time to expiry.

#### e) Warrants

Warrants transactions are summarized as follows:

|               |                    | Exercise        |               |            | Expired /    |             |              |
|---------------|--------------------|-----------------|---------------|------------|--------------|-------------|--------------|
| Granted       | Expiry             | Price           | June 30, 2020 | Granted    | Cancelled    | Exercised   | Dec 31, 2020 |
|               |                    |                 |               |            |              |             |              |
| July 24, 2018 | Dec 31, 2020       | \$ 0.30         | 8,560,800     | -          | (8,560,800)  | -           | -            |
| July 24, 2018 | July 24, 2020      | \$ 0.175        | 1,194,210     | -          | (1,194,210)  | -           | -            |
| July 24, 2018 | Dec 31, 2020       | \$ 0.35         | 13,454,249    | -          | (7,989,071)  | (5,465,178) | -            |
| Sept 18, 2018 | Dec 31, 2020       | \$ 0.35         | 16,775        | -          | (16,775)     | -           | -            |
| June 5, 2019  | June 5, 2022       | \$ 0.20         | 2,500,000     | -          | -            | -           | 2,500,000    |
| June 7, 2019  | June 7, 2021       | \$ 0.40         | 4,241,654     | -          | -            | -           | 4,241,654    |
| Dec 19, 2019  | Dec 19, 2021       | \$ 0.13         | 13,324,998    | -          | -            | -           | 13,324,998   |
| May 1, 2020   | May 1, 2022        | \$ 0.05         | 20,450,000    | -          |              | (1,000,000) | 19,450,000   |
| Nov 18, 2020  | Nov. 18, 2022      | \$ 0.13         | -             | 17,019,000 | -            | -           | 17,019,000   |
|               | Total              |                 | 63,742,686    | 17,019,000 | (17,760,856) | (6,465,178) | 56,535,652   |
|               |                    |                 |               |            |              |             |              |
|               | Weighted average   | ge              |               |            |              |             |              |
|               | exercise price     |                 |               | 0.13       | 0.11         | 0.09        | 0.13         |
| Weighted av   | erage remaining co | ontractual life |               |            |              | 1.35 years  |              |

c) Warrants (continued)

During the month period ended December 31, 2020, the Company received approval from the TSXV Exchange to extend the expiry dates and reduce the exercise price of the following warrants:

- 5,934,780 share purchase warrants at an exercise price of \$0.30 per share extended to December 31, 2020, which were schedule to expire on July 24, 2020. The exercise price was reduced to \$0.10.
- 13,454,249 share purchase warrants at an exercise price of \$0.35per share extended to December 31, 2020, which were schedule to expire on July 24, 2020. The exercise price was reduced to \$0.10.
- 16,775 share purchase warrants at an exercise price of \$0.35 per share extended to December 31, 2020, which were schedule to expire on July 24, 2020. The exercise price was reduced to \$0.10.

For details on warrants granted in the current year, refer to Note 10.

The following weighted-average assumptions used in the option-pricing model of warrants issued during the period December 31, 2020 and 2019:

|                         | December 31, 2020 | December 31, 2019 |
|-------------------------|-------------------|-------------------|
| Share price             | \$0.085           | \$0.045           |
| Risk-free interest rate | 0.27%             | 1.69%             |
| Expected life           | 2 years           | 2 years           |
| Expected volatility     | 111.28%           | 84%               |
| Expected dividends      | Nil               | Nil               |

Volatility is based on peer companies. Expected life is considered to be the time to expiry.

#### **12. RELATED PARTY TRANSACTIONS**

The Company considers its executive officers and directors to be key management personnel. The Company incurred the following amounts to related parties during the respective periods for key management personnel compensation:

|  | \$      | \$      |
|--|---------|---------|
| During the Six-Month Period ended December 31, | 2020    | 2019    |
| Total salaries, benefits and management fees   | 272,497 | 157,245 |
| Stock-based compensation                       | 79,459  | 89,518  |
| Total salaries and other short-term benefits   | 351,956 | 246,763 |

Included in accounts payable as at December 31, 2020 is \$449,175 (June 30, 2020: \$337,682) payable to Directors and Officers of the Company for management wages. The amount is non-interest bearing and unsecured.

On December 23, 2019, management and board members participated in a non-brokered private placement financing of units ("**Units**") for gross proceeds of \$250,000 at a price of \$0.06 per Unit. Each Unit consists of one common share and one warrant, with each warrant entitling the holder thereof to purchase one common share in the capital of the Company at a price of \$0.13 per share for a period of two years from closing, subject to acceleration.

On November 18, 2020, management and board members participated in a non-brokered private placement financing of units ("**Units**") for gross proceeds of \$373,500 at a price of \$0.05 per Unit. Each Unit consists of one common share and one warrant, with each warrant entitling the holder thereof to purchase one common share in the capital of the Company at a price of \$0.13 per share for a period of two years from closing, subject to acceleration.

As at December 31, 2020, the company had \$832,249 (June 30, 2020: \$770,485) of related party convertible debt related to a private placement financing on May 4, 2020 for gross proceeds of \$1,022,500 at a price of \$1.00 per Unit. Each Unit is comprised of \$1.00 principal amount of secured convertible debentures and 20 common share purchase.

#### **13. CANADA EMERGENCY WAGE SUBSIDY**

The Company applied for and received the Canada Emergency Wage Subsidy ("CEWS"), which provides up to 75% of an employee's wages, up to a maximum of \$847 per week. The initial program was in place for a 12-week period, from March 15 to June 6, 2020 and included three distinct claiming periods. The Company received \$25,548 each for the first and second reporting periods.

During the six-month period ended December 31, 2020, the company received \$83,727 (December 31, 2019: \$Nil) for the period from May 10 to November 21, 2020.

#### **14. FINANCIAL INSTRUMENTS**

The following table summarizes the classification and measurement for each financial instrument:

| Financial instrument         | Measurement                                 |
|------------------------------|---|
| Cash and cash equivalents    | Fair value through profit or loss ("FVTPL") |
| Accounts receivable          | Amortized cost                              |
| Other receivable             | Amortized cost                              |
| Accounts payable and accrued | Amortized cost                              |
| liabilities                  |   |
| CEBA Loan                    | Amortized cost                              |
| Convertible debenture        | Amortized cost                              |

Financial instruments are initially recognized at fair value on the consolidated statements of financial position. Subsequent measurement of financial instruments is based on their classification. Financial assets and liabilities classified at FVTPL are measured at fair value with changes in those fair values recognized in the consolidated statements of operations and comprehensive loss. Financial assets and liabilities classified at amortized cost are measured at amortized cost using the effective interest method.

#### Financial assets

The Company classifies its financial assets into the following categories, depending on the purpose for which the asset was acquired. Management determines the classification of its financial assets at initial recognition. Financial assets are derecognized when the contractual rights to cash flows from the financial asset receipt or when the contractual rights to those assets are transferred.

#### Amortized cost

Financial assets measured at amortized cost are financial assets held within a business model whose objective is to collect contractual cash flows, with the cash flows representing solely payments of principal and interest. These assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial assets are measured at amortized cost using the effective interest method, less any impairment losses. Financial assets measured at amortized cost include accounts receivable and other receivable. The amortized cost of these assets is representative of their fair value due to the short-term nature of these receivables.

#### FVTPL

Financial instruments are classified as FVTPL when they are held for trading. A financial instrument is held for trading if it was acquired for the purpose of sale in the near term. Financial instruments classified as FVTPL are measured at fair value, with any changes in fair value recognized in net loss.

#### 14. FINANCIAL INSTRUMENTS (continued)

#### Financial liabilities

Management determines the classification of its financial liabilities at initial recognition.

#### Amortized cost

Financial liabilities measured at amortized cost are recognized initially at fair value net of any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. Other financial liabilities are de-recognized when the obligations are discharged, cancelled or expired.

Financial liabilities are classified as current liabilities if payment is due within one year or less. If not, there are presented as non-current liabilities.

The fair value hierarchy that prioritizes the inputs used to measure fair value is as follows:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 Inputs that are not based on observable market data.

The fair value of cash is determined based on Level 1 inputs which consist of quoted prices in active markets for identical assets. As at December 31, 2020 and June 30, 2020, the Company believes that the carrying values of cash and cash equivalents approximate the fair values because of their nature and relatively short maturity dates or durations.

#### **15. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT**

The Company's financial instruments are exposed to a number of risks that are summarized below:

#### Credit Risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its trade receivables. The carrying value of these financial assets represents the Company's maximum exposure to credit risk. As at December 31, 2020, the Company had \$535,511 (June 30, 2020 - \$406,851) financial assets that may be subject to credit risk defaults (note 5). Cash is deemed to have a nominal risk as it is primarily held at a tier 1 Canadian chartered bank.

#### 15. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT (continued)

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations with respect to financial liabilities as they fall due. The Company's financial liabilities consist of its accounts payable CEBA loans payable and convertible debentures. The Company manages its liquidity risk through the management of its capital structure as described in Note 18. The Company's accounts payable have contractual maturities of 30 days or are due on demand, do not generally bear interest and are subject to normal trade terms. As at December 31, 2020, the Company held \$1,543,116 (June 30, 2020 - \$987,100) in accounts payable and accrued liabilities.

#### Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, investment fluctuations, and equity prices. Market conditions will cause fluctuations in the fair values of financial assets classified as fair value through profit or loss, and cause fluctuations in the fair value of future cash flows for assets or liabilities measured at fair value. As at December 31, 2020 and June 30, 2020, the Company holds \$1,022,500 of interest-bearing debt, however there is no cash flow interest rate risk because the interest rate is fixed at 10% (Note 10).

#### Foreign exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the foreign currency exchange rates. Revenue and expenses are mostly denominated in Canadian dollar, US dollar or Euro. A significant change in the currency exchange rates between the Canadian dollar, US dollar and Euro could have an effect on the Company's results of operations, financial position or cash flows. However, because most of the Company's financial instruments are denominated in Canadian dollars, the Company does not believe it is subject to any significant foreign exchange risk at this time. The Company has not hedged its exposure to currency fluctuations.

#### **16. CAPITAL MANAGEMENT**

The Company considers capital to be the elements of loans payable and shareholders' equity. The Company's primary objectives in capital management are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and to maintain sufficient funds to finance its business development and meet its obligations as they come due. The Company is in the early stages of operations and is currently developing a capital structure which will support expanded activity. The Company monitors economic conditions and the risks related to the underlying assets and business opportunities. The Company does not presently utilize any quantitative measures to monitor its capital and is not subject to externally imposed capital requirements

#### **17. SUPPLEMENTAL CASH FLOW INFORMATION**

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statement of cash flows.

During the six-month period ended December 31, 2020:

On September 14, 2020, the Company issued 144,229 shares in lieu of severance obligations to former senior officers valued at \$12,259 (Note 11).

On December 9, 2020, the Company issued 6,031,363 units valued to \$753,920 pursuant to licensing agreement entered with Lexaria Canpharm ULC. (Note 8).

During the six-month period ended December 31, 2019:

There were no significant non-cash transactions during the three-month period ended December 31, 2019.

#### **18. SUBSEQUENT EVENTS**

On January 31, 2021, 518,027 stock options expired unexercised.

On February 17, 2021, the Company issued 450,000 common shares pursuant to the conversions of convertible debt (Note 10) with a fair of \$22,500.

On March 1, 2021, the Company announced that it has granted stock options to purchase 4,800,000 common shares of the Company at an exercise price of \$0.095 per share pursuant to the stock option plan of the Company. The options were granted to existing employees, officers and directors of the Company.